Solomon Tesfaye

Solomon Tesfaye is a Consultant Physician/Endocrinologist at Sheffield Teaching Hospitals and Honorary Professor of Diabetic Medicine at the University of Sheffield. He qualified as a doctor in 1984 at the University of Bristol was trained in diabetes and diabetic neuropathy by his mentor Professor John D Ward. His research projects include the epidemiology, risk factors, pathogenesis, central nervous system involvement and treatment of diabetic neuropathy and neuropathic pain. He has published a book, over 150 original articles, reviews and book chapters in the field of diabetic neuropathy including a landmark study in the New England Journal of Medicine.

Professor Tesfaye was awarded the Prestigious Camillo Golgi Prize of the European Association for the Study of Diabetes (EASD) in 2014 for major scientific contributions in Diabetic Neuropathy. He has had international leadership roles including chairmanship of the International Expert Group on Diabetic Neuropathy that published 7 consensus recommendation papers in 2010/11; and of NEURODIAB (2006-9) which is the largest diabetic neuropathy scientific group in the world. He is also a member of the Science and Research Advisory Group of Diabetes UK; a review panel member for the Developmental Pathway Funding Scheme ((DPFS) of the MRC, a Board Member of the Global Quantitative Sensation Testing Society; a member of the Advisory Council of the Neuropathy Trust and is Secretary of International Insulin Foundation. He is currently the Associate Editor of Experimental Diabetes Research, Frontiers in Endocrinology, European Endocrinology and Diabetes Management and was previous Associate Editor of Diabetologia. Professor Tesfaye also serves as a grant review panel member for the JDRF and NIDDK; and has been a member of 3 NICE guideline committees on neuropathic pain management.  Finally, he has received several research grants including:  5 project grants from Diabetes UK, JDRF, NIH, EFSD, NIHR and a recent £2.97m HTA award to investigate the most effective treatment pathway for painful diabetic neuropathy.